Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsUnited KingdomApr 08, 2026, 6:16 PM ETAutolus Therapeutics plc (AUTL) StockSA Transcripts159.24K FollowersCommentsAutolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights April 8, 2026 1:00 PM EDTCompany ParticipantsAmanda Cray - Executive Director of Investor Relations & External CommunicationsMatthias Will - Senior VP & Chief Development OfficerChristian Itin - CEO & DirectorConference Call ParticipantsJae H. ParkLori MufflyElias JabbourMichael PulsipherPresentationOperatorGood day, everyone, and welcome to the Autolus investor event, Spotlight on Acute Lymphoblastic Leukemia, ALL, Program. [Operator Instructions]Now it's my pleasure to turn the call over to Amanda Cray. Please proceed.Amanda CrayExecutive Director of Investor Relations & External CommunicationsThank you, Carmen. Good afternoon or good evening, everyone, and thank you for joining us for today's presentation. With me are Chief Executive Officer, Dr. Christian Itin; and Chief Development Officer, Dr. Matthias Will.Before we get started, I'd like to remind you that during today's call, we will make statements related to our business that are forward-looking under federal securities laws. These may include, but are not limited to, statements regarding the status of development plans, clinical trials and market opportunities for obe-cel. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements.Also, please note that in today's presentation, we will discuss AUCATZYL, which is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia or B-ALL. The safety information of AUCATZYL includes a boxed warning for cytokine release syndrome, neurologic toxicities and secondary hematological malignancies. Please refer to the full prescribing information for additional important safety information.With that, I'm pleased to turn it over to Matthias.Read more current AUTL analysis and newsView all earnings call transcriptsCommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.